COMUNICADO: SIRveNIB, un estudio a gran escala del cáncer de hígado primario en la región Asia-Pacífico, completa el reclutamiento (

1) Study to Compare Selective Internal Radiation Therapy (SIRT) Versus Sorafenib in
Locally Advanced Hepatocellular Carcinoma (SIRveNIB):
http://clinicaltrials.gov/ct2/show/NCT01135056. http://www.sirvenib.com  
2) Llovet J, Ricci S, Mazzaferro V et al for the SHARP Investigators Study Group.
Sorafenib in advanced hepatocellular carcinoma. New England Journal of Medicine 2008;
359: 378-390.
3) Cheng A, Kang Y, Chen Z et al.  Efficacy and safety of sorafenib in patients in the
Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised,
double-blind, placebo-controlled trial.  Lancet Oncology 2009; 10: 25-34.
4) Sangro B, Carpanese L, Cianni R et al on behalf of European Network on
Radioembolization with yttrium-90 resin microspheres (ENRY). Survival after90Y resin
microsphere radioembolization of hepatocellular carcinoma across BCLC stages: A
European evaluation. Hepatology 2011; 54: 868-878.
5) Ferlay J, Soerjomataram I, Ervik M et al. Globocan 2012. v1.0, Cancer Incidence and
Mortality Worldwide: IARC CancerBase No. 11 [Internet]. Lyon, France: International
Agency for Research on Cancer; 2013. Available from: http://globocan.iarc.fr, accessed
on 06/June/2016.
6) European Association for the Study of the Liver, European Organisation for Research
and Treatment of Cancer. EASL-EORTC clinical practice guidelines: Management of
hepatocellular carcinoma. Journal of Hepatology 2012; 56: 908-943.

SIR-Spheres(R) is a registered trademark of Sirtex SIR-Spheres Pty Ltd.

329-EUA-0616

CONTACTO: Información para los medios de comunicación: Contacto: BiancaLippert, PhD, blippert@sirtex.com, +49 228 1840 783, Kenneth Rabin, PhD,krabin@sirtex.com, +48 502 279 244, Rachel Tan, rachel.tan.c.h@nccs.com.sg,+65 62 369 535